Compare USBC & SWKH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
| Metric | USBC | SWKH |
|---|---|---|
| Founded | N/A | 1996 |
| Country | | United States |
| Employees | 24 | N/A |
| Industry | | Diversified Financial Services |
| Sector | | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 221.2M | 205.9M |
| IPO Year | N/A | N/A |
| Metric | USBC | SWKH |
|---|---|---|
| Price | $0.36 | $16.58 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $18.00 |
| AVG Volume (30 Days) | ★ 435.9K | 5.3K |
| Earning Date | N/A | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $52.93 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $9.18 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.38 | $13.00 |
| 52 Week High | $1.97 | $18.66 |
| Indicator | USBC | SWKH |
|---|---|---|
| Relative Strength Index (RSI) | 32.41 | 33.27 |
| Support Level | N/A | $16.65 |
| Resistance Level | $0.53 | $17.71 |
| Average True Range (ATR) | 0.04 | 0.25 |
| MACD | 0.00 | -0.05 |
| Stochastic Oscillator | 4.84 | 11.83 |
USBC Inc is a multi-disciplinary technology company that is an innovator in digital financial technologies. The company develops financial services including digital assets and banking solutions, as well as non-invasive health monitoring research. USBC has implemented a Bitcoin treasury strategy to support development and research across its various divisions. A key focus is the further development of its tokenized deposit program, a tokenized representation of a U.S.-dollar-denominated bank deposit account that operates on blockchain technology and is embedded with digital identity, alongside its legacy non-invasive sensor technology business, with the objective of creating long-term shareholder value in an evolving financial landscape.
SWK Holdings Corp is a healthcare capital provider. The company offers financing solutions to various life science companies, institutions, and inventors. It involves monetizing cash flow streams derived from commercial-stage products and related intellectual property through royalty purchases and financings, as well as through the creation of synthetic revenue interests in commercialized products. Through its wholly-owned subsidiary, it also provides non-discretionary investment advisory services to institutional clients. The company's operating segments are Finance Receivables and Pharmaceutical Development Services. It generates maximum revenue from the Finance Receivables segment.